https://pharmoniq.com/news/fda-warning-letters-telehealth-compounded-glp1-weight-loss-drugs PharmoniQ en 2026-06-20T14:10:49.857Z FDA Issues 25 Warning Letters to Telehealth Firms Over Compounded GLP-1 Safety FDA enforcement, compounded drugs, GLP-1 agonists, telehealth, weight loss medications https://pharmoniq.com/news/fda-investigation-retail-supplement-safety-failures PharmoniQ en 2026-06-20T08:47:02.953Z FDA Investigation Exposes Widespread Safety Failures in Retail Supplements FDA, herbal supplements, safety standards, quality control, retail supplements https://pharmoniq.com/news/once-weekly-hiv-pill-phase-3-trials-breakthrough PharmoniQ en 2026-06-19T14:10:50.131Z Once-Weekly HIV Pill Clears Phase 3 Trials in Treatment Milestone HIV treatment, clinical trials, antiretroviral therapy, patient adherence, pharmaceutical innovation